



Fig. S9. Proposed model for PF-07062119 anti-tumor activity in combination with checkpoint blockade and anti-angiogenesis agents.

PF-07062119 redirects CD3+ T cells to GUCY2C positive tumor cells and elicits a cytotoxic T cell response through release of cytotoxic granules from T cells. This activity induces expression of checkpoint agents, PD-L1 on tumor cells and PD-1 on T cells. Checkpoint blockade with Anti-PD-1/PD-L1 mAbs results in improved PF-07062119 mediated CTL activity. Additionally,

combination of PF-07062119 with anti-angiogenesis agents also enhances anti-tumor activity and is associated with increased T cell infiltration.